Fabrus, LLC, a La Jolla, CA-based early stage biotechnology company focused on discovering and developing antibody therapeutics, has received $2m in equity financing.
![](https://www.finsmes.com/wp-content/uploads/2011/04/opko_logo_thumbnail1.jpg?w=120)
In conjunction with the financing, Phillip Frost, M.D., OPKO, and Jane Hsiao, Vice Chairman and CTO, OPKO, will join Fabrus’ Board of Managers.
Opko acquired approximately 13% of Fabrus’ outstanding membership interests on a fully diluted basis.
The funds will be used to develop drug candidates.
FinSMEs
04/11/2010